Next Generation Theranostics

circles design

TetraKit: Next Generation Theranostics

Targeted radionuclide therapy is an emerging field that has shown great promise in the treatment of late-stage metastatic cancer. Theranostics combines radionuclide therapy with diagnosis by nuclear imaging. In theranostics, cancer-targeting molecules, known as radiopharmaceuticals, carry radioactive atoms specifically to tumors. Depending on which type of radiation is chosen, physicians can either diagnose the severity and spread of the cancer or treat it by selectively destroying the cancerous tissue. TetraKit is a new, click chemistry based radiochemical platform, which allows for labeling of virtually any cancer-targeting molecule with any radionuclide pair for theranostics. TetraKit Technologies focuses its development program on fluorine-18 and astatine-211 as this pair is the best suited radionuclide pair for PET imaging and targeted alpha-radionuclide therapy. Alpha-therapy has attracted wide interest in current oncology as it succeeded where conventional therapies failed. TetraKit will develop the next generation of theranostic radiopharmaceuticals, which will improve patient care and disease outcomes.

Logo transparent

Latest news

from TetraKit Technologies

March 16, 2023

EMIM 2023

Our Chief Scientific Officer, Matthias Herth, is attending the 18th European Molecular Imaging Meeting #EMIM2023 this week in Salzburg, Austria.

As one of the major events in molecular imaging, EMIM brings together experts from various disciplines to share their latest research findings and network with peers.

We are proud to have Dr. Herth represent Tetrakit Technologies at this important event.

Follow us for more updates on our work in molecular imaging!

Read more

March 16, 2023

๐ŸŽ‰ Exciting News Alert! ๐ŸŽ‰

We are proud to announce that Tetrakit Technologies has officially joined the prestigious Venture House at BioInnovation Institute! ๐Ÿข๐Ÿ”ฌ

This is a significant milestone for our team, and we couldn’t be happier to be part of such an inspiring ecosystem of innovative biotech and life sciences startups. ๐ŸŒ

A big thank you to the entire Tetrakit team for their relentless passion, dedication, and hard work that has led us to this incredible opportunity. ๐Ÿ™Œ

We also want to express our gratitude to the BioInnovation Institute for recognizing our potential and providing us with this exceptional platform to grow, collaborate, and make a lasting impact in the world of biotechnology. ๐Ÿงช๐Ÿ’ก

As we embark on this new journey, we’re more motivated than ever to push boundaries, develop groundbreaking solutions, and, ultimately, improve the lives of millions around the globe. ๐ŸŒ๐Ÿ’Š

Stay tuned for more updates on our progress and the exciting developments to come! ๐Ÿš€


Read more

March 15, 2023

Welcome, Nadia!

A warm welcome to our newest team member, Nadia. With experience in organic and biomolecular chemistry, Nadia brings knowledge and expertise to our team. Nadia is part of our collaboration with the University of Copenhagen for the development of theranostics targeting the neuropeptide Y1 receptor.

  • Nadia, can you tell us briefly about your background? 

Sure, I graduated from the Technical University of Denmark with an MSc in Applied Chemistry. Through my previous project, I obtained key competencies in biomolecular design, synthesis, characterization, and planning and running bioassays. I am highly motivated to work with biomolecular chemistry because of the urgent need and high applicability in modern diagnostics and medicine.

  • What attracted you to our team, and what excites you most about your new role? 

TetraKit develops unique radiolabeling based on click chemistry to facilitate cancer diagnosis and therapy. I am happy to be part of the TetraKit team during my Ph.D. fellowship, as I see my research profile fitting within these objectives. Especially, I am excited to be working with a talented team and contributing to further developing the TetraKit solutions. In my new role, I look forward to expanding my expertise working with radiopharmaceutical chemistry, which will allow me to utilize my skills in the development of theranostics.

  • What are your long-term career goals? 

As a Ph.D. fellow, I wish to expand my scientific profile and conduct high-level research. This role is ideal for me to do so. The skills and experience I gain in this role will give me a unique set of professional skills of high value for my future carrier.

We are thrilled to have Nadia on board and look forward to this cooperation. Welcome to the team, Nadia!

Read more

Message from the CEO

Andreas Jensen, PhD

Andreas Jensen, PhD

Chief Executive Officer

Message from the CEO

โ€œTargeted radionuclide therapy has been demonstrated to be very effective in oncology. However, a practical and universal labeling platform has thus far not been developed. TetraKit Technologies will develop such a platform. We expect that this platform will bring more powerful treatments to patients, especially with advanced metastatic cancer.โ€

Message from the CSO

Matthias Herth, PhD

Matthias Herth, PhD

Chief Scientific Officer

Message from the CSO

โ€œTetraKit Technologies does not only provide a new platform enabling kit-labeling of almost any targeting vector with any radionuclide, but will also apply this technology to develop NextGen Theranostics based on the theranostic radionuclide pair fluoride-18 and astatine-211.โ€